BR112020004935A2 - Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular - Google Patents
Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celularInfo
- Publication number
- BR112020004935A2 BR112020004935A2 BR112020004935A BR112020004935A BR112020004935A2 BR 112020004935 A2 BR112020004935 A2 BR 112020004935A2 BR 112020004935 A BR112020004935 A BR 112020004935A BR 112020004935 A BR112020004935 A BR 112020004935A BR 112020004935 A2 BR112020004935 A2 BR 112020004935A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- lysyl
- trna synthetase
- pharmaceutical composition
- active ingredient
- Prior art date
Links
- 102000017737 Lysine-tRNA Ligase Human genes 0.000 title abstract 4
- 108010092041 Lysine-tRNA Ligase Proteins 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000012292 cell migration Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 3
- 230000005012 migration Effects 0.000 abstract 3
- 238000013508 migration Methods 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
Abstract
composição farmacêutica compreendendo um anticorpo que se kiga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular. a presente invenção refere-se a um novo uso de um anticorpo que se liga especificamente aon-terminal da lisil-trna sintetase e mais particularmente, a uma composição farmacêutica compreendendo um anticorpo que se liga especificamente a um epítopo incluindo a sequência da seq id no: 117 no domínio n-terminalda lisil-trna sintetase (krs) ou um fragmento funcional do mesmo como um princípio ativo para prevenir e tratar uma doença relacionada à migração de células imunes. um anticorpo específico para o n-terminal da krs fornecido pela presente invenção pode regular a migração de células imunes, exibindo assim efeitos muito notáveis na prevenção, alívio e tratamento de doenças relacionadas à migração de células imunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170118917 | 2017-09-15 | ||
PCT/KR2018/010903 WO2019054819A1 (ko) | 2017-09-15 | 2018-09-17 | 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112020004935A2 true BR112020004935A2 (pt) | 2022-04-19 |
BR112020004935A8 BR112020004935A8 (pt) | 2022-07-05 |
Family
ID=65723723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020004935A BR112020004935A8 (pt) | 2017-09-15 | 2018-09-17 | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular |
Country Status (10)
Country | Link |
---|---|
US (1) | US11965038B2 (pt) |
EP (1) | EP3682898A4 (pt) |
JP (1) | JP2020534273A (pt) |
KR (1) | KR102163465B1 (pt) |
CN (1) | CN111629752B (pt) |
AU (1) | AU2018332491B2 (pt) |
BR (1) | BR112020004935A8 (pt) |
CA (1) | CA3084461A1 (pt) |
RU (1) | RU2749591C1 (pt) |
WO (1) | WO2019054819A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2739393C1 (ru) | 2017-03-27 | 2020-12-23 | БайоконТАК Ко., Лтд. | АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕСЯ C N-КОНЦЕВОЙ ОБЛАСТЬЮ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, ЭКСПОНИРОВАННОЙ НА КЛЕТОЧНОЙ МЕМБРАНЕ |
CA3084461A1 (en) * | 2017-09-15 | 2019-03-21 | Medicinal Bioconvergence Research Center | Pharmaceutical composition comprising antibody binding specifically to lysyl-trna synthetase n-terminus as effective ingredient for preventing or treating immune cell migration-related disease |
CA3117001C (en) * | 2018-09-17 | 2023-09-19 | Biocontac Co., Ltd. | Antibody for specifically binding to lysyl-trna synthetase n-terminal domain exposed to extracellular membrane |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9928136D0 (en) * | 1999-11-29 | 2000-01-26 | Rose Marlene L | Organ rejection and associated conditions |
KR100961392B1 (ko) | 2008-04-15 | 2010-06-07 | 이화여자대학교 산학협력단 | 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터 |
RU2465330C1 (ru) * | 2008-08-18 | 2012-10-27 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ПОСРЕДСТВОМ СНИЖЕНИЯ КЛЕТОЧНОГО УРОВНЯ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ (ВАРИАНТЫ), КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ВЕКТОРА ЭКСПРЕССИИ ИЛИ АНТИТЕЛА ПРОТИВ KRS ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК |
CA2734892A1 (en) * | 2008-08-18 | 2010-02-25 | Seoul National University Industry Foundation | Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
KR101009501B1 (ko) * | 2008-10-10 | 2011-01-18 | 서울대학교산학협력단 | 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물 |
EP2509625B1 (en) * | 2009-12-11 | 2015-01-28 | Atyr Pharma, Inc. | Histidyl trna synthetases for reducing inflammation |
EP2575857B1 (en) * | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
WO2015102341A1 (ko) * | 2013-12-30 | 2015-07-09 | 재단법인 의약바이오컨버젼스연구단 | 항 krs 모노클로날 항체 및 이의 용도 |
US11111396B2 (en) | 2014-10-17 | 2021-09-07 | C3 Nano, Inc. | Transparent films with control of light hue using nanoscale colorants |
US10050713B2 (en) | 2015-03-02 | 2018-08-14 | Futurewei Technologies, Inc. | Optical transceiver using duplex media, self-homodyne detection (SHD), coherent detection, and uncooled laser |
KR20180069146A (ko) | 2016-12-14 | 2018-06-25 | 만도헬라일렉트로닉스(주) | 주차 조향 보조 시스템 및 그 제어방법 |
RU2739393C1 (ru) * | 2017-03-27 | 2020-12-23 | БайоконТАК Ко., Лтд. | АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕСЯ C N-КОНЦЕВОЙ ОБЛАСТЬЮ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, ЭКСПОНИРОВАННОЙ НА КЛЕТОЧНОЙ МЕМБРАНЕ |
CA3084461A1 (en) * | 2017-09-15 | 2019-03-21 | Medicinal Bioconvergence Research Center | Pharmaceutical composition comprising antibody binding specifically to lysyl-trna synthetase n-terminus as effective ingredient for preventing or treating immune cell migration-related disease |
-
2018
- 2018-09-17 CA CA3084461A patent/CA3084461A1/en active Pending
- 2018-09-17 KR KR1020180111060A patent/KR102163465B1/ko active IP Right Grant
- 2018-09-17 JP JP2020515025A patent/JP2020534273A/ja active Pending
- 2018-09-17 BR BR112020004935A patent/BR112020004935A8/pt unknown
- 2018-09-17 EP EP18856914.9A patent/EP3682898A4/en active Pending
- 2018-09-17 US US16/646,240 patent/US11965038B2/en active Active
- 2018-09-17 AU AU2018332491A patent/AU2018332491B2/en active Active
- 2018-09-17 WO PCT/KR2018/010903 patent/WO2019054819A1/ko unknown
- 2018-09-17 CN CN201880074372.5A patent/CN111629752B/zh active Active
- 2018-09-17 RU RU2020113539A patent/RU2749591C1/ru active
Also Published As
Publication number | Publication date |
---|---|
BR112020004935A8 (pt) | 2022-07-05 |
KR20190031189A (ko) | 2019-03-25 |
US20210070880A1 (en) | 2021-03-11 |
CA3084461A1 (en) | 2019-03-21 |
CN111629752A (zh) | 2020-09-04 |
AU2018332491A1 (en) | 2020-04-30 |
KR102163465B1 (ko) | 2020-10-07 |
RU2749591C1 (ru) | 2021-06-15 |
EP3682898A4 (en) | 2021-09-29 |
AU2018332491B2 (en) | 2022-04-14 |
EP3682898A1 (en) | 2020-07-22 |
WO2019054819A1 (ko) | 2019-03-21 |
JP2020534273A (ja) | 2020-11-26 |
US11965038B2 (en) | 2024-04-23 |
CN111629752B (zh) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
BR112018008805A2 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
BR112016001753A2 (pt) | Anticorpo, anticorpo ou seu fragmento, composição de anticorpo, célula, composição farmacêutica, produto de droga de combinação e método de tratamento e/ou prevenção de câncer | |
BR112018002196A2 (pt) | formulação anti-ifnar1 estável | |
BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
BR112022003589A2 (pt) | Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo | |
BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
BR112021018506A2 (pt) | Terapia de combinação para tratamento do câncer | |
BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
BR112019023260A2 (pt) | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
BR112016011727A2 (pt) | Antagonistas de gastrina para o tratamento e prevenção de osteoporose | |
BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: BIOCONTAC CO., LTD. (KR) |
|
B25A | Requested transfer of rights approved |
Owner name: ZYMEDI CO., LTD. (KR) |